Collectively, these findings suggest that PGRN, through its triple mechanisms of inhibiting inflammation, facilitating tissue repair, and orchestrating metabolic balance, offers a multifunctional therapeutic strategy for metabolic disorders characterised by cartilage destruction and dysregulated bone remodelling. The gene discussed is GRN; the disease is metabolic disease.